Silver Book Fact

Five-year health care resource use in medically managed SAS patients

Clark M, Arnold S, Duhay F, Thompson A, et al. Five-Year Clinical and Economic Outcomes Among Patients with Medically Managed Severe Aortic Stenosis: Results from a Medicare claims analysis. Circulation: Cardiovascular Quality and Outcomes. 2012; 5(5). http://circoutcomes.ahajournals.org/content/5/5/697

Reference

Title
Five-Year Clinical and Economic Outcomes Among Patients with Medically Managed Severe Aortic Stenosis: Results from a Medicare claims analysis
Publication
Circulation: Cardiovascular Quality and Outcomes
Publication Date
2012
Authors
Clark M, Arnold S, Duhay F, Thompson A, et al.
Volume & Issue
Volume 5, Issue 5
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • 1 and 6-month mortality rates without treatment for sSAS
    Waiting for treatment for severe symptomatic aortic stenosis (sSAS) can be deadly, with 1-month mortality at 3.7% and 6-month mortality at 11.6% (measured from the time intervention was recommended).  
  • Prevalence of AS in Americans 75+
    An estimated 12.4%, or ~2.5 million people ages 75+ in North America, have AS.  
  • Survival rates for SAS patients without treatment
     
  • Detection rate of heart murmurs
    More than 40% of heart murmurs — detected with a stethoscope and sometimes the first sign of heart valve disease (HVD) — are missed by family practitioners.  
  • Aortic valve disease costs
    Aortic valve disease (AVD) (symptomatic and asymptomatic) costs the U.S. $10.2 billion in direct costs each year.